ONCOLOGY

Cochrane reviews radical prostatectomy vs deferred treatment approach.

Results from a phase 2 study.

Expert guidance on the use of PSMA PET/CT to assess treatment response in prostate cancer.

Guidelines address disease management, salvage radiotherapy, and relapse.

Avelumab improved OS in JAVELIN BLADDER trial.

Survivors should be counseled about maintaining a healthy weight.

Key recommendations in hormone-naive metastatic and castration-resistant disease.

The final appraisal decision can be appealed up to 10 July 2020

OS and cancer-specific survival were similar vs long-term ADT.

The treatment will be available under the Cancer Drugs Fund

10-year database study of low- and intermediate-risk patients.

Multigene prostate cancer liquid biopsy is intended for diagnosis, monitoring.

Clinicians should consider these risks in patients unlikely to benefit from nerve sparing.

Final OS analysis of phase 3 PREVAIL study.